CENTESSA-Icon-Logo

Brett Zbar MD

Managing Director and Global Head of Life Sciences

General Atlantic

Dr. Brett Zbar, MD, serves as Managing Director and Global Head of Life Sciences at General Atlantic, a leading global growth equity firm providing capital and strategic support for growth companies.

Before joining General Atlantic in 2020, Brett was a Managing Director at Foresite Capital, where he focused on backing leading healthcare entrepreneurs and companies at all stages. While at Foresite, Brett served as a board member or observer at multiple companies, including ConnectiveRx, Kinnate Biopharma, ORIC Pharmaceuticals (OTCMKTS: OCLDY), Peloton Therapeutics (acquired by Merck & Co.), Pharvaris, Replimune (NASDAQ: REPL), Signant Health, Turning Point Therapeutics (NASDAQ: TPTX) and VenatoRx Pharmaceuticals.

Prior to that, Brett was a Partner at Aisling Capital, where he invested in life sciences companies developing and commercializing innovative products, services and technologies.

Brett began his career in McKinsey & Company’s Pharmaceuticals and Medical Products practice and completed his internship in internal medicine on the Osler Medical Service at Johns Hopkins Hospital. He received his MD from Harvard Medical School and holds a BA in English and Molecular Biophysics and Biochemistry from Yale University.

Back to Board of Directors
Scroll to Top
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678, NCT05789524, NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B